Dimerix

Dimerix Limited is a clinical-stage biotechnology company discovering and developing new therapeutic approaches in Australia. The company's lead product candidate is DMX-200, which has completed Phase IIa clinical trials for the treatment of chronic kidney disease. Its product pipeline also includes programs for liver inflammation, ophthalmic/otologic diseases, and allergy/inflammation.